The HYDRASHIFT daratumumab and isatuximab in vitro (IVD) diagnostic test resulting of a collaboration between Sebia, Janssen and Sanofi to provide the clinical community with better tools to monitor patients with multiple myeloma in line with the International Myeloma Group’s (IMWG) latest recommendations.
These assays, intended to be used with HYDRAGEL IF, mitigates the daratumumab or isatuximab mediated interference seen in immunofixation results for patients treated with DARZALEX® or SARCLISA®, a fully human monoclonal antibody that binds to CD38.
The benefit of HYDRASHIFT has been highlighted in several scientific publications, such as the Journal of Applied Laboratory Medicine (JALM) by AACC by Thoren, Ola Landgren et al., which shows:
- HYDRASHIFT benefits for myeloma patients who are receiving daratumumab therapy through more accurate monitoring of their disease status.
- The HYDRASHIFT 2/4 daratumumab assay is a useful tool to clarify the source of an IgGk band on immunofixation and allow a patient’s M protein to be viewed without interference.
HYDRASHIFT
Avoid interferences due to therapeutic Monoclonal Antibody with HYDRASHIFT Portfolio.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country.
Please contact your local Sebia representative. Information intended for healthcare professionals.
Carefully read the instructions in the reagent package inserts and instrument manuals.